Welcome to our dedicated page for Xenon Pharmaceuticals SEC filings (Ticker: XENE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Xenon Pharmaceuticals Inc. filings document a Nasdaq-listed Canadian biopharmaceutical issuer developing ion channel modulators for neurological and psychiatric disorders. Recent Form 8-K reports cover operating results, Regulation FD clinical disclosures, azetukalner study updates, investor presentation materials and exhibits tied to company press releases.
The filing record also includes proxy materials for shareholder voting and executive compensation, amendments to inducement equity incentive plans, registration and prospectus materials for common-share sales, pre-funded warrant and underwriting agreements, at-the-market offering disclosures, and capital-structure information for XENE common shares.
Xenon Pharmaceuticals Inc. is filing a prospectus supplement to offer up to $400,000,000 of common shares through an at-the-market equity program with Jefferies LLC and Stifel, Nicolaus & Company as sales agents.
The prospectus supplement replaces a prior prospectus and states that $291,084,564 of Shares have previously been sold under the Sales Agreement. The offering contemplates sales on the Nasdaq Global Market at prices that will vary; the supplement cites a last reported sale price of $44.92 per share on February 26, 2026. The disclosure notes estimated underwriting commissions up to 3.0%, customary indemnities to agents, intended uses of proceeds to fund clinical development and corporate purposes, and that there is no escrow arrangement. Shares outstanding were 80,010,790 as of December 31, 2025.
Xenon Pharmaceuticals filed its annual report describing a late-stage neuroscience pipeline led by azetukalner, a Kv7 potassium channel opener in multiple Phase 3 trials for focal onset and primary generalized tonic-clonic seizures, as well as major depressive disorder and bipolar depression.
The company highlights strong Phase 2b X-TOLE epilepsy data showing meaningful seizure reductions and generally manageable side effects, plus proof-of-concept antidepressant results from X-NOVA supporting the Phase 3 MDD and BPD programs. Early-stage Nav1.7, Nav1.1 and Kv7 pain programs and a sodium-channel collaboration with Neurocrine further expand its ion-channel portfolio.
Xenon Pharmaceuticals reported a larger net loss in 2025 as it ramped up late-stage clinical development of its lead epilepsy and mood-disorder drug azetukalner. Net loss was $345.9 million for 2025, compared with $234.3 million in 2024, driven mainly by higher research and development spending.
Research and development expenses rose to $300.9 million in 2025 from $210.4 million, reflecting multiple Phase 3 studies in epilepsy, major depressive disorder and bipolar depression, as well as early-stage pipeline work. General and administrative expenses increased to $79.6 million from $68.9 million.
Cash, cash equivalents and marketable securities were $586.0 million as of December 31, 2025, and pro forma cash including first-quarter 2026 at-the-market share sales was $716.0 million. The company raised $242.2 million through its at-the-market facility and expects its cash to fund operations into the second half of 2027, while key Phase 3 azetukalner data readouts begin in March 2026.
Wellington Management has disclosed a sizeable institutional stake in Xenon Pharmaceuticals Inc. (XENE). As of December 31, 2025, Wellington entities report beneficial ownership of 4,764,779 shares of Xenon common stock, representing about 6.17% of the outstanding shares.
Across the listed Wellington entities, there is no sole voting or dispositive power; voting and investment decisions are reported as shared over most of these shares. The filing explains that the securities are owned of record by Wellington investment-adviser clients, who receive dividends and sale proceeds, while no single client holds more than five percent of the class. Wellington certifies the position is held in the ordinary course of business and not for the purpose of influencing control of Xenon.
Xenon Pharmaceuticals Inc. reported a new equity award for its Chief Medical Officer, Christopher John Kenney. On January 9, 2026, he received a share option covering 100,000 common shares with an exercise price of $42.15 per share. This option vests 25% on January 9, 2027, with the remaining 75% vesting in equal monthly installments over the next three years, encouraging longer-term retention.
On the same date, he was also granted 20,000 restricted share units, each representing a right to receive one common share. These RSUs vest in four equal 25% installments on each of the first four anniversaries of the grant date, beginning January 9, 2027. Both awards are reported as directly owned and reflect equity-based compensation rather than any sale of existing shares.
Xenon Pharmaceuticals Inc. reported new equity awards to its Chief Commercial Officer, Darren S. Cline. On January 9, 2026, he received a share option for 40,000 common shares with an exercise price of $42.15 per share, all held directly. This option vests 25% on January 9, 2027, with the remaining 75% vesting in equal monthly amounts over the following three years.
On the same date, he was also awarded 20,000 restricted share units, each representing a contingent right to receive one common share. These RSUs vest in four equal installments of 25% on each of the first four anniversaries of the grant date, beginning on January 9, 2027. Both awards are reported as directly owned derivative securities following the transactions.
Xenon Pharmaceuticals Inc. Chief Legal Officer Andrea DiFabio reported new equity awards. On January 9, 2026, DiFabio received share options covering 80,000 common shares at an exercise price of $42.15 per share, with no purchase price for the grant itself. These options vest 25% on January 9, 2027, with the remaining 75% vesting in equal monthly installments over the following three years.
On the same date, DiFabio was also granted 15,000 restricted share units, each representing a contingent right to receive one common share. These RSUs vest 25% on each of the first four anniversaries of the grant date, beginning January 9, 2027. Both awards are reported as directly held derivative securities.
Xenon Pharmaceuticals Inc. President & CEO Ian Mortimer reported new equity awards. On January 9, 2026, he received a stock option for 350,000 common shares at an exercise price of $42.15 per share. This option vests 25% on January 9, 2027, with the remaining 75% vesting in equal monthly installments over the following three years.
He also received 65,000 restricted share units, each representing a contingent right to receive one common share. These restricted share units vest 25% on each of the first four anniversaries of the grant date, beginning January 9, 2027. Both the option and the restricted share units are reported as directly owned.
Xenon Pharmaceuticals Inc.’s president and CEO, who is also a director, reported open-market sales of company common shares under a Rule 10b5-1 trading plan. On 12/05/2025 the insider sold 14,375 common shares at a weighted-average price of $45.03 per share. On 12/08/2025 additional trades involved 8,820 shares at a weighted-average $45.59 and 2,010 shares at a weighted-average $46.32, each executed in multiple transactions within stated price ranges. Following these sales, the insider beneficially owns 6,000 common shares directly and 14,300 common shares indirectly through a spouse; the Rule 10b5-1 trading plan was adopted on September 27, 2024.
Xenon Pharmaceuticals (XENE) reported Q3 2025 results with a net loss of $90.9 million (basic and diluted loss per share $1.15). The quarter had no collaboration revenue; year-to-date revenue was $7.5 million from a Neurocrine milestone tied to NBI-921355 entering a Phase 1 study.
Operating expenses rose as late-stage programs advanced: R&D was $77.1 million and G&A was $19.3 million in Q3. Interest income was $6.2 million. Cash, cash equivalents and marketable securities totaled $555.3 million as of September 30, 2025, and management expects this to fund operations for at least the next 12 months. Net cash used in operations for the first nine months was $197.6 million.
Pipeline updates: the Phase 3 X‑TOLE2 study in focal onset seizures completed enrollment (380 randomized) with topline data anticipated in early 2026; Phase 3 X‑TOLE3 (FOS) and X‑ACKT (PGTCS) continue. Phase 3 programs in MDD (X‑NOVA2/3) and bipolar depression (X‑CEED) are underway. Early-stage pain candidates include XEN1701 (Nav1.7) and XEN1120 (Kv7) in Phase 1.